ArticleCancer medicine2026
Pattern and Clinical Significance of CA19-9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative Analytical Performance and Clinical Agreement of Chemiluminescence Microparticle Immunoassay and Electrochemiluminescence Immunoassay for CA19-9: A Diagnostic Accuracy Study.Diagnostics (Basel, Switzerland) · 2026Article
- Efficacy of immune checkpoint inhibitors combined with chemotherapy for advanced gastric cancer.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbohydrate antigen 19-9 (CA19-9) is a cell surface glycoprotein widely used as a diagnostic and prognostic serum marker for monitoring pancreatic cancer. The aim of this study was to evaluate the prevalence and clinical relevance of CA19-9 expression in human cancer.
methodsTo comprehensively determine the prevalence and clinical relevance of CA19-9 expression in cancer, a tissue microarray containing 14,966 samples from 134 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.
resultsThe staining results were categorized into four groups according to the percentage of CA19-9-positive tumor cells and the staining intensity. At least an occasional CA19-9 positivity was found in 79 of 134 tumor categories with 66 containing at least one strongly positive case. CA19-9 positivity was most frequent in biliopancreatic adenocarcinomas (84.4%-95.4%), adenocarcinomas of the upper and lower gastrointestinal tract (54.7%-74.4%), embryonal carcinomas of the testis (93.5%), and endometrioid endometrial carcinomas (87.5%). High CA19-9 staining was associated with advanced pT-stage, pN1, L1 (p < 0.0001 each), V1 (p = 0.0239), mismatch repair protein deficiency (p = 0.0067), and BRAF V600E mutation (p = 0.0005) in colorectal adenocarcinoma. Reduced CA19-9 staining was associated with distant metastasis (p = 0.0067) in clear cell renal cell carcinoma, advanced pT-stage (p = 0.0277) in papillary renal cell carcinoma, high grade (p = 0.0129) in breast cancer and with invasive tumor growth (pTa vs. pT2-4, p < 0.0001) and high grade (p = 0.0367) in urothelial carcinoma.
conclusionsIt is concluded that a high CA19-9 expression, as found in pancreatic adenocarcinoma, occurs in subsets of various other cancer types. Patients with such tumors could potentially benefit from CA19-9 serum monitoring, for example in terms of response to treatment, recurrence or predicting prognosis. Cancer type dependent associations between high or low CA19-9 expression and aggressive tumor phenotype are in line with the complex and variable functional role described for CA19-9 in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.